Synthesis, characterisation, activities, cell uptake and DNA binding of a trinuclear complex: [[trans-PtCl(NH3)]2mu-[trans-Pd(NH3)(2-hydroxypyridine)-(H2)N(CH2)6NH2)2]Cl4.

@article{Cheng2006SynthesisCA,
  title={Synthesis, characterisation, activities, cell uptake and DNA binding of a trinuclear complex: [[trans-PtCl(NH3)]2mu-[trans-Pd(NH3)(2-hydroxypyridine)-(H2)N(CH2)6NH2)2]Cl4.},
  author={H T Cheng and Fazlul Huq and Philip Beale and Keith J. Fisher},
  journal={European journal of medicinal chemistry},
  year={2006},
  volume={41 7},
  pages={
          896-903
        }
}
  • H. Cheng, F. Huq, K. Fisher
  • Published 1 July 2006
  • Chemistry, Biology
  • European journal of medicinal chemistry

Synthesis, characterization, cytotoxicity, and DNA binding of some new platinum(II) and platinum(IV) complexes with benzimidazole ligands

TLDR
In this study, two Pt(II) and three Pt(IV) complexes with the structures of [PtL2Cl2] were synthesized and evaluated for their in vitro antiproliferative activities against the human MCF-7, HeLa, and HEp-2 cancer cell lines.

Synthesis and Activity of a Trinuclear Platinum Complex: [{trans‐PtCl(NH3)2}2μ‐{trans‐Pt(3‐hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in Ovarian Cancer Cell Lines

TLDR
Th1 has the potential to be developed into a highly active anticancer drug with a wider spectrum of activity than cisplatin and has been able to significantly overcome resistance in A 2780cisR and A2780ZD0473R cell lines.

Neutral and ionic platinum compounds containing a cyclometallated chiral primary amine: synthesis, antitumor activity, DNA interaction and topoisomerase I-cathepsin B inhibition.

TLDR
Remarkable cytotoxicity was observed for most of the synthesized Pt(ii) compounds regardless of (i) the absolute configuration R or S, and (ii) the coordinated/cyclometallated (neutral or cationic) nature of the complexes.

Synthesis and structure of a new thiazoline-based palladium(II) complex that promotes cytotoxicity and apoptosis of human promyelocytic leukemia HL-60 cells

TLDR
PdPyTT produced a time- and dose-dependent decrease in cell viability and increased intracellular ROS production and DNA oxidative damage, which demonstrated the promising application of palladium(II) complexes as novel anti-leukemic agents.

Novel Pd(II)-salen complexes showing high in vitro anti-proliferative effects against human hepatoma cancer by modulating specific regulatory genes.

TLDR
The synthesis of a novel salen ligand and its mononuclear Pd-salen complexes derived from 2-hydroxy-3-{[(E)-(2-hydroxyphenyl)methylidene]amino}propyl)imino]methyl}phenol and the results suggest that Pd(II) complexes bind to DNA strongly as compared to the free ligand.

References

SHOWING 1-10 OF 10 REFERENCES

Kinetic and equilibria studies of the aquation of the trinuclear platinum phase II anticancer agent [(trans-PtCl(NH(3))(2))(2)(mu-trans-Pt(NH(3))(2)(NH(2)(CH(2))(6)NH(2))(2))](4+) (BBR3464).

TLDR
The hydrolysis profile of the bifunctional trinuclear phase II clinical agent has been examined and suggests that the dichloro form predominates.

Cytotoxicity and antitumor activity of bis(platinum) complexes. A novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes.

The in vitro cytotoxicity and in vivo antitumor activity of bis(platinum) complexes of general formula [(PtX2-(L))2H2N(CH2)nNH2] (L = NH3, X = Cl or X2 = malonato or where L = py, X = Cl) is

Cooperative effects in long-range 1,4 DNA-DNA interstrand cross-links formed by polynuclear platinum complexes: an unexpected syn orientation of adenine bases outside the binding sites

TLDR
Examination of the structure of the BBR3464 cross-link adduct reveals unusual cooperative effects unique to this class of anticancer drugs and is the first demonstration of cooperative effects in solution for an anticancer drug.

Comparative cytotoxicity of CI‐973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines

TLDR
The results suggest that CI‐973 and teatraplatin may have potential utility in some cases of cisplatin‐resistant ovarian cancer, and are consistent with the existence of at least 2 platinum‐resistance phenotypes.

Recent insights into platinum drug resistance in cancer.

Rapid isolation of eukaryotic DNA.

  • D. Bowtell
  • Biology, Chemistry
    Analytical biochemistry
  • 1987